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AN ORAL METHADONE PROGRAM 
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ABSTRACT 
OBJECTIVES: To compare the prevalence of Staphylo-
coccus aureus and methicillin-resistant S. aureus (MRSA) car-
riage among injection drug users (IDUs) treated in an injection 
heroin maintenance program with that among IDUs treated in an 
oral methadone program, and to determine predictors of S. 
aureus carriage. 
DESIGN: Survey. 
SETTING: Two opiate maintenance programs at a psy-
chiatric university clinic. 
PARTICIPANTS: A volunteer sample consisting of 94 
(74%) of 127 IDUs treated in an injection opiate maintenance pro-
gram with at least twice daily injections of heroin, and 70 (56%) of 
125 IDUs treated in an oral methadone program. 
RESULTS: Addicts treated in the intravenous heroin sub-
stitution program had a significantly lower overall rate of S. 
aureus carriage (37 of 94 [39.4%] vs 42 of 70 [60%]; P = .009) and 
a significantly lower rate of nasal carriage (21 of 94 [22.3%] vs 30 
of 70 [42.9%]; P = .005) than did addicts treated in the oral 
methadone program. Being treated in the oral methadone pro-
gram was the only independent predictor of S. aureus carriage 
(odds ratio, 2.27; 95% confidence interval, 1.19-4.31; P= .012). All 
S. aureus isolates were susceptible to oxacillin. 
CONCLUSIONS: The regular use of needles under asep-
tic conditions did not increase the rate of S. aureus carriage 
among IDUs. Further studies are necessary to investigate 
whether the lower rate of S. aureus carriage among IDUs treated 
with intravenous heroin leads to a lower incidence of S. aureus 
infections in these patients {Infect Control Hosp Epidemiol 
2004;25:133-137). 
Staphylococcus aureus is the main pathogen causing 
bacterial infections among injection drug users. The spec-
trum of infections caused by this organism in injection 
drug users includes endocarditis, bloodstream infections, 
arthritis, osteomyelitis, cellulitis, and skin abscesses.1 
Soft tissue infections, predominantly caused by S. aureus,1 
are one of the main reasons for emergency department 
visits and hospital admissions of injection drug users.23 
Furthermore, antimicrobial-resistant S. aureus, such as 
methicillin-resistant S. aureus (MRSA), may cause out-
breaks among injection drug users.4 Such an outbreak 
recently occurred in Switzerland.5 
Colonization with S. aureus, particularly nasal car-
riage of S. aureus, plays a key role in the pathogenesis and 
increases the risk of S. aureus infection.6,7 However, the 
biological mechanisms of nasal colonization by S. aureus 
are still unclear.8 Tuazon and Sheagren showed that active 
injection drug users have a higher rate of S. aureus colo-
nization of the skin and nose than does the general popu-
lation.9 This finding and the observation of higher rates of 
S. aureus carriage among patients with insulin-dependent 
diabetes mellitus, patients receiving hemodialysis or con-
tinuous ambulatory peritoneal dialysis, and patients 
undergoing desensitization therapy with allergen injec-
tions led to the hypothesis that repeated puncture of the 
skin by needles or catheters increases the rate of S. 
aureus carriage, even under strict aseptic conditions.610 
The first aim of the current study was to analyze the 
association between intravenous drug use and S. aureus 
carriage by comparing the rate of S. aureus colonization 
among injection drug users treated in an injection opiate 
maintenance program with at least twice daily injections 
of heroin with that among injection drug users treated in 
a conventional oral methadone program. Second, we 
assessed the prevalence of MRSA colonization among 
injection drug users treated in these two opiate mainte-
nance programs in Basel, Switzerland. 
M E T H O D S 
Study Population 
All injection drug users treated in two opiate mainte-
nance programs in Basel between April 1 and June 30, 
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TABLE 1 
CHARACTERISTICS OF THE PATIENTS TREATED IN THE ORAL 
METHADONE PROGRAM AND IN THE INTRAVENOUS HEROIN 
MAINTENANCE PROGRAM 
TABLE 1 (Cont'd) 
CHARACTERISTICS OF THE PATIENTS TREATED IN THE ORAL 
METHADONE PROGRAM AND IN THE INTRAVENOUS HEROIN 
MAINTENANCE PROGRAM 
Characteristic 
No. of patients 
Mean age, y (+ SD) 
Women 
Intravenous drug 
addiction > 10 y 
Staphylococcus aureus carriage 
S. aureus carriers 
(nose, pharynx, or skin) 
Nasal S. aureus carriers 
Pharyngeal S. aureus 
carriers (pharynx only) 
Drug use in the month 
preceding the study 
Patients 
Receiving 
Oral 
Methadone 
70 
35 (± 6) 
26 (37.1%) 
45 (64.3%) 
42 (60%) 
30 (42.9%) 
10 (14.3%) 
Patients 
Receiving 
Intravenous 
Heroin 
94 
36 (± 6) 
24 (25.5%) 
72 (76.6%) 
37 (39.4%) 
21 (22.3%) 
15 (16%) 
P 
.310 
.110 
.085 
.009 
.005 
.768 
Characteristic 
Hospitalizations 
Hospitalization in the 
year preceding the 
S. aureus screening 
Hospitalization in the 
month preceding the 
S. aureus screening 
Patients 
Receiving 
Oral 
Methadone 
12 (17.1%) 
7 (10%) 
Patients 
Receiving 
Intravenous 
Heroin P 
16 (17%) .984 
4 (4.3%) .207 
SD - standard deviation; HIV - human immunodeficiency virus. 
*At the time of the study, this patient in the intravenous heroin program was treated with oral 
methadone only, as intravenous or intramuscular injections were not possible. 
tDiagnosis could be verified through available results of the determination of antibody to 
hepatitis C virus and antibody to hepatitis B core antigen IgG for all 94 patients in the intra-
venous heroin program and for 49 of 70 patients in the oral methadone program. 
*Only 1 of these 9 patients used nasal steroids. 
No injection drug use 
Heroin use 
Intravenous heroin 
Intramuscular heroin 
Heroin smoking 
Heroin snorting 
Cocaine use 
Intravenous cocaine 
Intramuscular cocaine 
Cocaine smoking 
Cocaine snorting 
Heroin or cocaine smoking 
Oral methadone 
Intravenous methadone 
Intramuscular methadone 
Cannabis smoking 
Intravenous use of 
street drugs 
Needle exchange 
Diseases 
HIV infection 
Atopic dermatitis or eczema 
Psoriasis 
Skin abscess (at the time 
of S. aureus screening) 
Allergic rhinitis 
Asthma 
History of hepatitis Bf 
History of hepatitis Cf 
Medications 
Antibiotics 1 to 6 mo prior to 
S. aureus screening 
Antibiotics in the month 
preceding the S. aureus 
screening 
Nasal medications' 
24 (34.3%) 
24 (34.3%) 
17 (24.3%) 
1 (1.4%) 
3 (4.3%) 
6 (8.6%) 
34 (48.6%) 
28 (40%) 
2 (2.9%) 
6 (8.6%) 
4 (5.7%) 
8 (11.4%) 
58 (82.9%) 
29 (41.4%) 
1 (1.4%) 
6 (8.6%) 
42 (60%) 
1 (1.4%) 
14 (20%) 
9 (12.9%) 
4 (5.7%) 
11 (15.7%) 
9 (12.9%) 
5 (7.1%) 
40 (57.1%) 
47 (67.1%) 
10 (14.3%) 
9 (12.9%) 
5 (7.1%) 
1 (1.1%)* 
92 (97.9%) 
88 (93.6%) 
6 (6.4%) 
2 (2.1%) 
2 (2.1%) 
33(35.1%) 
32 (34%) 
2 (2.1%) 
3 (3.2%) 
2 (2.1%) 
3 (3.2%) 
46 (48.9%) 
6 (6.4%) 
0 
25 (26.6%) 
42 (44.7%) 
0 
6 (6.4%) 
9 (9.6%) 
5 (5.3%) 
9 (9.6%) 
6 (6.4%) 
8 (8.5%) 
65 (69.1%) 
73 (77.7%) 
12 (12.8%) 
4 (4.3%) 
4 (4.3%) 
<.001 
<.001 
<.001 
.240 
.652 
.074 
.083 
.433 
1.0 
.172 
.403 
.056 
<.001 
<.001 
.427 
.004 
.052 
.427 
.506 
1.0 
.235 
.155 
.748 
.113 
.133 
.778 
.044 
.498 
2001, were asked to participate in the study. The first pro-
gram is a traditional oral methadone program. Patients 
receive their oral methadone doses every day or at least 
weekly. The second program is an intravenous heroin sub-
stitution program and enrolls severely addicted patients for 
whom other treatments have failed.311 Participants receive 
and have to inject the prescribed dose of heroin at the clin-
ic under direct supervision, usually twice daily. They have 
to use the sterile injection equipment provided. In addition 
to heroin, patients are given oral methadone if needed. 
Risk Factors for S. aureus Carriage 
Information on drug use in and outside the pro-
gram, medications, medical conditions, and risk factors 
for S. aureus carriage was collected from all participants 
by questionnaire, and checked by chart review. All of the 
participants underwent an interview and a skin examina-
tion performed by one of the investigators. 
Microbiological Studies 
Specimens were obtained from the anterior nares, 
the pharynx, and, if present, skin wounds with a sterile 
polyester fiber-tipped swab moistened with sterile saline. 
Swabs were transported to the laboratory in a transport 
tube (Transwab MW170, Medical Wire & Equipment, 
Corsham, United Kingdom) and cultured within 24 hours 
in Chapman broth (7.5% NaCl) at 35° C overnight. A loop 
was then subcultured on Columbia sheep blood agar with 
colistin and nalidixic acid. After incubation at 35° C for 24 
hours, colonies with morphology consistent with S. 
aureus were identified by Gram stain, catalase test, latex 
agglutination test for the detection of clumping factor, pro-
tein A, and capsular polysaccharides of S. aureus 
(Pastorex Staph-Plus, Bio-Rad, Marnes-la-Coquette, 
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France), and tube coagulase test. Susceptibility testing for 
oxacillin was performed with oxacillin screening agar 
plates (6 mg/L) according to National Committee for 
Clinical Laboratory Standards guidelines.12 
Statistical Analysis 
Categorical variables were compared using a two-
sided chi-square test or Fisher's exact test and continuous 
variables using a t test. Independent predictors of S. 
aureus carriage were determined by multiple stepwise 
logistic regression analysis. All variables with a P value of 
.10 or less were entered into the model. Statistical analy-
ses were performed using SPSS software (version 10.1.3; 
SPSS, Inc., Chicago, IL). 
The study was approved by the Research Ethics 
Committee of the Cantons Basel Stadt and Basel Land. 
Written informed consent was obtained from each study 
participant. 
RESULTS 
Study Population 
Seventy (56%) of 125 patients from the oral 
methadone program and 94 (74%) of 127 patients from the 
intravenous heroin program agreed to participate in the 
study. The demographic data of study participants and 
characteristics that could affect the rate of S. aureus car-
riage are presented in Table 1. None of the study partici-
pants suffered from insulin-dependent diabetes mellitus. 
Only 1 patient, an S. aureus carrier, used nasal steroids, 
and 2 female patients used estrogens (1 was colonized 
with S. aureus). 
S. aureus Carriage 
The addicts treated in the intravenous heroin sub-
stitution program had a significantly lower overall rate of 
S. aureus carriage (ie, colonization of at least the nose, 
pharynx, or skin [37 of 94 (39.4%) vs 42 of 70 (60%); P = 
.009]) and a significantly lower rate of nasal carriage (21 
of 94 [22.3%] vs 30 of 70 [42.9%]; P = .005) than did the 
addicts treated in the oral methadone program. The 
prevalence of S. aureus carriers with colonization in the 
pharynx only was similar in the two groups (Table 1). 
Thirteen (54.2%) of 24 patients from the oral methadone 
program who did not inject drugs in the month preceding 
the study were S. aureus carriers. 
Risk Factors for S. aureus Carriage 
Characteristics associated with S. aureus carriage 
are presented in Table 2. The following variables were 
included in the logistic regression analysis model: treat-
ment in the oral methadone program, use of intravenous 
heroin, heroin smoking, cocaine smoking, use of intra-
venous methadone, history of hepatitis C, and hospital-
ization in the month preceding the study. In this model, 
being treated in the oral methadone program was the 
only independent predictor of S. aureus carriage (odds 
ratio, 2.27; 95% confidence interval, 1.19 to 4.31; P = 
.012). 
Susceptibility to Oxacillin 
All S. aureus isolates were susceptible to oxacillin. 
DISCUSSION 
The overall rate of S. aureus carriage found in the 
current study among addicts treated in an intravenous 
heroin maintenance program (39.4%) is almost identical to 
the rate previously reported by Tuazon and Sheagren for 
active injection drug users (35%).9 The rate of nasal car-
riage of S. aureus (22.3%) is similar to the rate recently 
found among healthy university students (26.2%),13 and is 
lower than the mean rate of carriage of 37.2% in the gen-
eral population calculated by Kluytmans et al. from 18 
published studies involving 13,873 individuals.6 
The current study also showed that addicts inject-
ing heroin in the setting of a substitution program had a 
significantly lower overall rate of S. aureus carriage and a 
lower rate of nasal carriage than did addicts treated in an 
oral methadone program. They had an even lower rate of 
S. aureus carriage than those addicts in the oral 
methadone program who did not inject street drugs or 
methadone in the month preceding the study (39.4% vs 
54.2%). 
These findings suggest that the regular use of ster-
ile needles under aseptic conditions per se does not 
increase the rate of S. aureus carriage. This conclusion is 
consistent with the results of two previous studies. In the 
first study involving 217 active and former drug users, 
Holbrook et al. found no association between injection 
drug use and nasal colonization by S. aureus, although 
nasal carriage of S. aureus was independently correlated 
with inhalational drug use in individuals infected with 
human immunodeficiency virus.14 The second study 
demonstrated that the higher rate of nasal carriage of S. 
aureus found among patients receiving allergen-injection 
immunotherapy is probably related to the atopic constitu-
tion of these patients, manifested by a high prevalence of 
atopic dermatitis and eczema, rather than to the regular 
use of needles for the desensitization therapy.13 
It is unclear why treatment in the oral methadone 
program was associated with a higher rate of S. aureus 
carriage. The anterior nares are the ecologic niches of S. 
aureus and provide a reservoir from which the skin is col-
onized.6,8 It is not known exactly how S. aureus binds to 
the nasal mucosa. Previous studies described S. aureus 
adhesion to mucin,15 and to nasal epithelial cells.16 It is 
also thought that damaged mucosa is more likely to 
become colonized with S. aureus because underlying sur-
faces contain tissue constituents, such as microbial sur-
face components recognizing adhesive matrix molecules, 
that promote colonization.17 Sixty-six percent of the 
patients in the oral methadone program continued to use 
intravenous drugs despite methadone substitution. 
Addicts treated with oral methadone may inject or smoke 
contaminated street drugs more frequently and these may 
cause nasal mucosal damage. This illegal drug use may 
also take place in settings with poor hygiene and shared 
use of drug paraphernalia, thus facilitating transmission 
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TABLE 2 
CHARACTERISTICS OF STAPHYLOCOCCUS AUREUS CARRIERS (NASAL, 
PHARYNGEAL, OR SKIN COLONIZATION) AND OF NONCARRIERS 
TABLE 2 (Cont'd) 
CHARACTERISTICS OF STAPHYLOCOCCUS AUREUS CARRIERS (NASAL, 
PHARYNGEAL, OR SKIN COLONIZATION) AND OF NONCARRIERS 
Staphylococcus aureus Staphylococcus aureus 
Characteristic Carriers Noncarriers 
No. of patients 
Mean age, y (± SD) 
Women 
Intravenous drug 
addiction > 10 y 
Opiate maintenance 
treatment 
Intravenous heroin 
Oral methadone 
Drug use in the month 
preceding the study 
No injection drug use 
Heroin use 
Intravenous heroin 
Intramuscular heroin 
Heroin smoking 
Heroin snorting 
Cocaine use 
Intravenous cocaine 
Intramuscular cocaine 
Cocaine smoking 
Cocaine snorting 
Heroin or cocaine 
smoking 
Oral methadone 
Intravenous methadone 
Intramuscular methadone 
Cannabis smoking 
Intravenous use of 
street drugs 
Needle exchange 
Diseases 
HIV infection 
Atopic dermatitis or 
eczema 
Psoriasis 
Skin abscess (at the 
time of S. aureus 
screening) 
Allergic rhinitis 
Asthma 
History of hepatitis B* 
History of hepatitis C* 
Medications 
Antibiotics 1 to 6 mo 
prior to S. aureus 
screening 
Antibiotics in the month 
preceding the S. aureus 
screening 
Nasal medicationst 
79 
35 (± 6) 
27 (34.2%) 
54 (68.4%) 
37 (46.8%) 
42 (53.2%) 
14 (17.7%) 
54 (68.4%) 
45 (57%) 
5 (6.3%) 
5 (6.3%) 
5 (6.3%) 
31 (39.2%) 
26 (32.9%) 
3 (3.8%) 
7 (8.9%) 
3 (3.8%) 
7 (8.9%) 
50 (63.3%) 
22 (27.8%) 
1 (1.3%) 
12 (15.2%) 
44 (55.7%) 
1 (1.3%) 
11 (13.9%) 
10 (12.7%) 
3 (3.8%) 
12 (15.2%) 
6 (7.6%) 
7 (8.9%) 
50 (63.3%) 
53 (67.1%) 
9 (11.4%) 
7 (8.9%) 
4 (5.1%) 
85 
36 (± 6) 
23 (27.1%) 
63 (74.1%) 
57 (67.1%) 
28 (32.9%) 
11 (12.9%) 
62 (72.9%) 
60 (70.6%) 
2 (2.4%) 
0 
3 (3.5%) 
36 (42.4%) 
34 (40%) 
1 (1.2%) 
2 (2.4%) 
3 (3.5%) 
4 (4.7%) 
54 (63.5%) 
13 (15.3%) 
0 
19 (22.4%) 
40 (47.1%) 
0 
9 (10.6%) 
8 (9.4%) 
6 (7.1%) 
8 (9.4%) 
9 (10.6%) 
6 (7.1%) 
55 (64.7%) 
67 (78.8%) 
13 (15.3%) 
6 (7.1%) 
5 (5.9%) 
.234 
.322 
.415 
.009 
.009 
.395 
.519 
.069 
.263 
.024 
.484 
.685 
.346 
.353 
.090 
1.0 
.288 
.975 
.050 
.482 
.242 
.269 
.482 
.514 
.506 
.498 
.259 
.506 
.670 
.850 
.090 
.464 
.670 
1.0 
Characteristic Carriers Noncarriers 
Hospitalizations 
Hospitalization in the 
year preceding the 
S. aureus screening 
Hospitalization in the 
month preceding the 
S. aureus screening 
10 (12.7%) 18 (21.2%) 
; (10.1%) 3 (3.5%) 
.147 
.091 
SD - standard deviation; HIV = human immunodeficiency virus. 
*Diagnosis could be verified through available results of the determination of antibody to 
hepatitis C virus and antibody to hepatitis B core antigen IgG for all 94 patients in the intra-
venous heroin program and for 49 of 70 patients in the oral methadone program. 
fOnly 1 of these 9 patients used nasal steroids. 
of S. aureus.17 In fact, in the current study, the patients 
treated in the oral methadone program snorted heroin, 
smoked heroin or cocaine, and used intravenous 
methadone and intravenous street drugs more frequently 
than did the patients in the intravenous heroin program. 
These factors and additional factors other than the regu-
lar use of needles under aseptic conditions may interact 
and increase the rate of S. aureus colonization among 
injection drug users. A larger study population would be 
necessary to identify such factors. 
Complications associated with injection drug use 
are frequently the consequence of the illegal status of 
street drugs. Therefore, in several countries, harm reduc-
tion measures have been developed, including implemen-
tation of supervised injecting facilities where injection 
drug users are provided with sterile injecting equipment, 
opiate substitution programs, and programs offering 
intravenous heroin substitution to addicted patients for 
whom other treatments have failed.11 It has been shown 
that injection opiate maintenance programs improve 
health status and social functioning, reduce the self-
reported use of illicit drugs and criminal activity,1118 
reduce the incidence of hepatitis B and C,19 and may 
decrease the incidence of human immunodeficiency virus 
and hepatitis A virus infection.20 The current study found 
a low rate of S. aureus carriage among injection drug 
users in an intravenous heroin maintenance program. 
This low rate of S. aureus carriage may result in a low 
incidence of S. aureus infections in this population. This 
hypothesis is supported by a previous study showing a 
significant decrease in the prevalence of skin abscesses 
and cellulitis, which are predominantly caused by S. 
aureus,1 among injection drug users in an intravenous 
heroin program.21 
All S. aureus isolates of the current study in Basel 
were susceptible to oxacillin. This result is surprising con-
sidering the recent MRSA epidemic among injection drug 
users in the neighboring city of Zurich.5 However, this 
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finding mirrors the low MRSA prevalence (4%) among 
nosocomial S. aureus isolates in Basel,22 and suggests that 
the injection drug user populations in the two cities are 
not in close contact. This observation also illustrates the 
importance of regular surveillance of the local epidemio-
logic situation regarding antibiotic-resistant organisms. 
Addicts treated in an intravenous heroin mainte-
nance program had a lower rate of S. aureus carriage than 
did addicts treated in an oral methadone program. Factors 
other than the regular use of needles under aseptic con-
ditions may predispose injection drug users to S. aureus 
carriage. Further studies are necessary to investigate 
whether the lower rate of S. aureus carriage leads to a 
lower incidence of S. aureus infections among injection 
drug users treated with intravenous heroin. 
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